Literature DB >> 10325236

Mechanism of block and identification of the verapamil binding domain to HERG potassium channels.

S Zhang1, Z Zhou, Q Gong, J C Makielski, C T January.   

Abstract

Calcium channel antagonists have diverse effects on cardiac electrophysiology. We studied the effects of verapamil, diltiazem, and nifedipine on HERG K+ channels that encode IKr in native heart cells. In our experiments, verapamil caused high-affinity block of HERG current (IC50=143.0 nmol/L), a value close to those reported for verapamil block of L-type Ca2+ channels, whereas diltiazem weakly blocked HERG current (IC50=17.3 micromol/L), and nifedipine did not block HERG current. Verapamil block of HERG channels was use and frequency dependent, and verapamil unbound from HERG channels at voltages near the normal cardiac cell resting potential or with drug washout. Block of HERG current by verapamil was reduced by lowering pHO, which decreases the proportion of drug in the membrane-permeable neutral form. N-methyl-verapamil, a membrane-impermeable, permanently charged verapamil analogue, blocked HERG channels only when applied intracellularly. Verapamil antagonized dofetilide block of HERG channels, which suggests that they may share a common binding site. The C-type inactivation-deficient mutations, Ser620Thr and Ser631Ala, reduced verapamil block, which is consistent with a role for C-type inactivation in high-affinity drug block, although the Ser620Thr mutation decreased verapamil block 20-fold more than the Ser631Ala mutation. Our findings suggest that verapamil enters the cell membrane in the neutral form to act at a site within the pore accessible from the intracellular side of the cell membrane, possibly involving the serine at position 620. Thus, verapamil shares high-affinity HERG channel blocking properties with other class III antiarrhythmic drugs, and this may contribute to its antiarrhythmic mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325236     DOI: 10.1161/01.res.84.9.989

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  101 in total

1.  Field and action potential recordings in heart slices: correlation with established in vitro and in vivo models.

Authors:  Herbert M Himmel; Alexandra Bussek; Michael Hoffmann; Rolf Beckmann; Horst Lohmann; Matthias Schmidt; Erich Wettwer
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

5.  Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2.

Authors:  G Eichenbaum; M K Pugsley; D J Gallacher; R Towart; G McIntyre; U Shukla; J M Davenport; H R Lu; J Rohrbacher; V Hillsamer
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

6.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Authors:  Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2006-04-22       Impact factor: 6.343

Review 7.  Modification of K+ channel-drug interactions by ancillary subunits.

Authors:  Glenna C L Bett; Randall L Rasmusson
Journal:  J Physiol       Date:  2007-12-20       Impact factor: 5.182

8.  Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.

Authors:  Dierk Thomas; Sven Kathofer; Wei Zhang; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 9.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

10.  Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart.

Authors:  Saeed Sattari; William F Dryden; Lise A Eliot; Fakhreddin Jamali
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.